Avicanna Inc · TSX:AVCN
Avicanna — Investor Presentation (November 2026)
14 slides from Avicanna's investor presentation, November 2026
Slide 1: A Biopharmaceutical Leader in Cannabinoid-Based Medicine
A Biopharmaceutical Leader in Cannabinoid-Based Medicine Q4 2026 TSX: AVCN OTCQB: AVCNF FSE: 0NN avicanna.com
Slide 2: Integrated Cannabinoid-Based Biopharmaceutical Platform
Integrated Cannabinoid-Based Biopharmaceutical Platform An integrated commercial and scientific platform combining proprietary products, nationwide medical distribution, pharmaceutical development and international supply capabilities. Commercial & Medical Platform • 4 integrated commercial-stage bu
Slide 3: RHO Phyto™ | Proprietary Medical Cannabis Portfolio
RHO Phyto™ | Proprietary Medical Cannabis Portfolio Pharmaceutical-grade cannabinoid formulations Standardized cannabinoid formulations across multiple delivery systems Proprietary drug delivery systems designed to enhance bioavailability and dosing precision Supported by pre-clinical, clinical, and
Slide 4: Introducing QUIX™ Rapid Onset Portfolio
Introducing QUIX™ Rapid Onset Portfolio Designed for faster onset, enhanced bioavailability and next-generation cannabinoid products QUIX™ is Avicanna’s proprietary nano-emulsion-based drug delivery technology designed to address cannabinoid formulation challenges, including delayed onset and variab
Slide 5: MyMedi.ca™ | Medical Cannabis Care Platform
MyMedi.ca™ | Medical Cannabis Care Platform Avicanna’s proprietary, pharmacist-led platform connecting patients, practitioners and payers A nationwide medical cannabis care platform that supports patients from registration through ongoing treatment, combining a curated formulary, pharmacist-led clin
Slide 6: MyMedi.ca™ | Nationwide Medical & Commercial Infrastructure
MyMedi.ca™ | Nationwide Medical & Commercial Infrastructure A proprietary platform enabling patient access, real-world evidence, and commercialization of cannabinoid-based therapies Strategic Value • Direct engagement with patients, prescribers, and payers • Real-world evidence generation platform •
Slide 7: Six Integrated Pillars of Medical Cannabis Care
Six Integrated Pillars of Medical Cannabis Care A complete platform designed around the patient journey and the healthcare ecosystem 01 02 03 Portfolio & Digital Pharmacy & Patient Support & Formulary E-Commerce Clinical Services 200+ products • 35+ brands Registration • ordering • CRM Pharmacist-le
Slide 8: Pharmaceutical Pipeline | Status
Pharmaceutical Pipeline | Status Avicanna programs by development stage, with completed and ongoing work Program Formulation Preclinical RWE / Clinical Approved Completed Underway Observational Deep Tissue Gel Formulation; in vitro studies; observational MSK pain Phase II RCT design study (N≈115) CB
Slide 9: Global Commercial Platform | International Expansion
Global Commercial Platform | International Expansion Expanding cannabinoid-based pharmaceutical and medical products across international markets Commercial Presence and Potential • Historical commercial exports to 24 countries across six continents • Scalable platform supported by integrated API an
Slide 10: Established Scientific Platform & Institutional Validation
Established Scientific Platform & Institutional Validation Supporting the development of evidence-based cannabinoid therapeutics Scientific Platform • Proprietary formulation and delivery technologies • Clinical and pre-clinical research programs 60+ 3 Ongoing Clinical Trials • Real-world evidence g
Slide 11: Financial Highlights | Q3 2026
Financial Highlights | Q3 2026 Positive Adjusted EBITDA, stable margins and a leaner cost structure $5.73M 50.9% $0.22M 27% Q3 2026 revenue Gross margin (+1.7 pts Adjusted EBITDA G&A reduction YoY YoY) (+$1.01M YoY) Q3 2026 Performance Cost Discipline & Working Capital • Revenue of $5.73M; $18.05M f
Slide 12: Management and Board of Directors
Management and Board of Directors Senior Management Team Board of Directors AA Aras Azadian AA Aras Azadian Founder and CEO Founder and CEO NH Nick Hilborn LM Lisa McCormack Chief Financial Officer Independent Director SK Stephen Kim OK Ozgur Kilic Chief Legal Officer & General Counsel Independent D
Slide 13: Investment Highlights
Investment Highlights 01 02 03 Financial Inflection Commercial Scale Differentiated IP Positive Q3 Adjusted EBITDA and 68 proprietary SKUs and 178 QUIX™ launched commercially; materially reduced operating Canadian commercial listings PwdRx development advancing expenses 04 05 06 Integrated Medical P
Slide 14: Thank You
Thank You Q4 2026 TSX: AVCN OTCQB: AVCNF FSE: 0NN avicanna.com info@avicanna.com